Member Info for Moneysponge

Micky i also said the chart would at least fill the gap at 1.8p but was laffed at

Alistare said avacta funded to back end of next year and he laughed at any need for a fundraise in the short term

This is obvious from the accounts also if you dont take his word for it

The data is changing the conversation with pharmaceutical companies

this is platform technology not just a 1 of drug

avacta are seeing uptcik in commercial interest

There are plenty of non dilutive funding options anyway

Safety data is conclusively superior to straight dox

Efficacy data is at least as good and most likely way way way more efficacious than straight dox

There is nothing stopping this becoming a monster now, except sentiment in the general market.

All the dots are there and you dont need to be a genius to join them up

Did I hear that right?

wow!

Once you take AVA6000 then it should hit the tumour hard, possibly shrink it and it will also clear up any cancer that has started to spread around as well. Mop it all up.

Sellers and or shorters have lost the plot here

This moves much higher

Anyone done a cashrun way projection

At 26m and stripping out costs from aquisitions then it looks to me like Avacta have over a years worth of money

Immediately wipes out any funding concerns

Next thing is how do they fund the pivotal p2 trial and I think we all know the answer to that

PARTNERSHIP or LICENCING deal bring tens of millions of pounds into the coffers

The tech works and plenty saying they want it acc to EF

The company are financed

Avacta are in the driving seat

Nothing else needs to be said

Plenty enough to see company through well into 2024

Thats all that matters

As licencing or partnership deal will be signed after P1A results release

If heights converted at 118p then doesn't that show you people they expect this to rise from there significantly?

Otherwise why would they convert?

Anything around this price is an absolute gift

What do you mean sujood?

If we already have data for doxorubicn goig back half a century then what is p2 data going to tell us that we dont already know?

It is pure dox when split so for me this is justa formality and a licence to print money at this level

I dont care if that sounds like a ramp somebody tell me why ava6000 will not replace doxorubicn as standard of care and multiply the existing market of between 1 and 2 billion many times over.

Also tell me WHY the FDA WOULDN'T fast track this?

Honestly I dont know how you guys do it day in day out determined to make your money in boo when so many other better shares are rising now. Its the psychology of crystalising a loss I guess. Just too painful

its true though once out of a share that you see things way more objectively.

Boohoo still has a outlandish valuation for a company not expected to turn a profit until 2026. If the shares dont move in that period (and why would they) then the opportunity cost here alone is going to cripple people.

At least one thing is nobody is daft enough to put a leveraged spread bet on as that will really cost them dear.

22p remains a technical target here fwiw

HedgeHogarth is anything below 4p really a good entry?

The 6p isnt 100% confirmed as yet and even if it was, plenty have brought much higher

the chart is looking like filling that gap to about 1.8p before it tests support - willit or wont it hold?

This stock still remains very high risk with a very low chance of success

of course if it works then magic everyone is minted but the overwhelming majoiryt of clinical trials do not make it all the way thats just a fact

Its why Avacta is a much better prospect. It still offers the 10 - 100x upside potential but has a very high likelyhood of doing it given they have developed a new delivery system not a new drug so all efficacy data etc is already known and route to approval is much faster

Vlad here might have the science credentials but does he really have the business acumen needed like Avatas top team do? I just doubt it seriously from what I have learnt

Momentum now to the downside so the bottom gap will fill

if hemo do what they are expectig and it is a big if

then of course the upper gap will fill

I think the market conditions are largely to blame but surely nearing the end of the bear market now

Investors are scared of there own shadows

Even slightest hint of a fundraise evokes intense emotions based on how fundraises have gone this past years

If you use your brain and keep calm you read the last RNS and are totally realxed

No doubt these will be a massive company with a market cap in the billions in the near term as well

Its not just covid laterla flow tests AVCT are able to or shotly able to do sepsis tests which is huge plus I read somewhere about bowl cancer tests. LFTs are used for food inteolerance and even for plant health care there is loads of uses for them and it is a growing market.

In terms of 100 odd a share then yeah why not. That is only what 30ish billion market cap

If AVA6000 does expand the existing market to 10bn+ then that one drug alone could get us to that valuation if were valued at just 3x sales. Few estimates out there now saying AVCT only need another 30m to bring AVA6000 to market themselves.

Then remember there is the full affirmer platform, ADC potential and the whole pipeline of precision drugs and the soon to be profitable diagnostics business.

Honestly, 30bn market cap will be nothing its deramping it if anything and is it really stupid to think 300bn is possible down the line so a thousand bagger. I really dont think so but at 100 bags most early entrance would be gone and not hold for the thousand. At 10bags we'll lose a lot and probably there will be many who go at 100% gain.

The amout fo money you make here seems just depending on how long you want to hold for. A good entry makes it easier to hold of course. Theres not many like this one that is for sure so you dont mess about trading it

AVCT board aren't boosters

Then Alistair comes out and says data they are seeing is "stunning"

P1A data release in just a few months time and we will see exactly what stunning means

Big pharma will be in the know already

Bidding war will break out and anyone not in will be locked out of what is a once in a generation stock

Imagine going back in time and looking at Apple, Amazon, Netflix shares and trading it in the early days because price ran into resistance hahahaha

Same people trading that in the pennies are now trading it for hundreds of pounds

All the had to do was hold on, JAdam :)

This has to be one of the WORST shares in the UK right now.

Truly shocking

Is that 22p target I told yall about at over 60p becoming more obvious to you people yet?

Just hope nobody here is daft enough to be using leverage ,well, not in the long direction anyway

This share is getting really easy to predict says JAdam who sold at 1.19 (clown emoji).

£100k buy

First of many :)

I dont have a second account

Chris I have had my eye on this for a while

The fact is it has done nothing but drop and you have done nothing but shout about the upside

I think you are blinded by it

The chart is clearly indicating a huge drop below 5p

I'll not post any more on here but just remember it was me that told you and others about AVCT the hundred bagger so we will let history decide who gave the better advice

Dont be fooled by its 300m market cap. It is high for good reason and yes it absolutely is a hundred bagger.

You think cos fab is cheap it is better and its just not true

GL if staying in here as you will need it

Https://investingstrategy.co.uk/biotech/investing-strategy-the-avacta-edit/

Just like I identified my lithium picks last week, I am keenly following four London-listed small cap oncology shares — each at very different stages and focusing on different areas of treatment.

Avacta (LON: AVCT)

Hemogenyx (LON: HEMO)

Cizzle (LON: CIZ)

Poolbeg Pharma (LON: POLB)

While the other companies are attractive investments on their own terms — with some also offering non-oncology based treatments — they are all blown out of the water by Avacta. There is simply no comparison from a risk-reward perspective. I am a supporter and investor in the other three, all of which are promising, but Avacta is simply in a different league